Evogene Ltd
EVGN1.030USD
-0.020-1.90%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
8.98MMarket Cap
LossP/E TTM
More Details of Evogene Ltd Company
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Evogene Ltd Info
Ticker SymbolEVGN
Company nameEvogene Ltd
IPO dateJun 11, 2007
CEOEmber (Brian)
Number of employees117
Security typeOrdinary Share
Fiscal year-endJun 11
Address13 Gad Feinstein Street
CityREHOVOT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code7638517
Phone97289311900
Websitehttps://evogene.com/
Ticker SymbolEVGN
IPO dateJun 11, 2007
CEOEmber (Brian)
Company Executives of Evogene Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Leon Yehuda Recanati
Mr. Leon Yehuda Recanati
Independent Director
Independent Director
83.89K
--
Dr. Arnon Heyman
Dr. Arnon Heyman
Chief Executive Officer of Canonic Limited
Chief Executive Officer of Canonic Limited
--
--
Mr. Ofer Haviv
Mr. Ofer Haviv
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Sarit Firon
Ms. Sarit Firon
Independent Director
Independent Director
--
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Independent Director
Independent Director
--
--
Kenny Green
Kenny Green
Investor Relations
Investor Relations
--
--
Ms. Dorit Kreiner
Ms. Dorit Kreiner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Dan Michael Falk
Mr. Dan Michael Falk
Independent Director
Independent Director
--
--
Dr. Brian Ember
Dr. Brian Ember
Chief Executive Officer of AgPlenus Limited
Chief Executive Officer of AgPlenus Limited
--
--
Dr. Nir Arbel
Dr. Nir Arbel
Chief Product Officer
Chief Product Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Leon Yehuda Recanati
Mr. Leon Yehuda Recanati
Independent Director
Independent Director
83.89K
--
Dr. Arnon Heyman
Dr. Arnon Heyman
Chief Executive Officer of Canonic Limited
Chief Executive Officer of Canonic Limited
--
--
Mr. Ofer Haviv
Mr. Ofer Haviv
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Sarit Firon
Ms. Sarit Firon
Independent Director
Independent Director
--
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Independent Director
Independent Director
--
--
Kenny Green
Kenny Green
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Other
4.00M
47.00%
United States
3.92M
46.00%
Israel
595.77K
7.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Recanati (Leon Yehuda)
0.96%
Citadel Advisors LLC
0.66%
Jane Street Capital, L.L.C.
0.45%
Morgan Stanley & Co. LLC
0.35%
Two Sigma Investments, LP
0.13%
Other
97.45%
Shareholders
Shareholders
Proportion
Recanati (Leon Yehuda)
0.96%
Citadel Advisors LLC
0.66%
Jane Street Capital, L.L.C.
0.45%
Morgan Stanley & Co. LLC
0.35%
Two Sigma Investments, LP
0.13%
Other
97.45%
Shareholder Types
Shareholders
Proportion
Individual Investor
0.96%
Research Firm
0.94%
Hedge Fund
0.79%
Investment Advisor
0.14%
Investment Advisor/Hedge Fund
0.06%
Other
97.10%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
51
144.62K
9.61%
--
2025Q3
53
144.62K
9.93%
--
2025Q2
54
144.62K
9.94%
-290.86K
2025Q1
54
436.41K
15.76%
-409.22K
2024Q4
55
411.93K
12.75%
-150.59K
2024Q3
55
562.52K
10.21%
+159.81K
2024Q2
56
414.42K
108.89%
-12.34K
2024Q1
61
426.75K
10.84%
-122.17K
2023Q4
68
460.98K
18.51%
-27.27K
2023Q3
74
506.57K
13.57%
+395.44K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Recanati (Leon Yehuda)
83.89K
0.96%
--
--
Mar 17, 2025
Citadel Advisors LLC
21.37K
0.25%
+21.37K
--
Jun 30, 2025
Jane Street Capital, L.L.C.
15.02K
0.17%
-18.71K
-55.46%
Jun 30, 2025
Morgan Stanley & Co. LLC
15.16K
0.17%
+600.00
+4.12%
Jun 30, 2025
Two Sigma Investments, LP
21.09K
0.24%
+7.53K
+55.50%
Jun 30, 2025
BNP Paribas Securities Corp. North America
14.12K
0.16%
+1.30K
+10.14%
Jun 30, 2025
P&S Vermögensberatungs AG Performance & Sicherheit
10.00K
0.11%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
4.20K
0.05%
--
--
Aug 31, 2025
UBS Financial Services, Inc.
6.73K
0.08%
-12.02K
-64.10%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 03, 2022
Merger
10→1
Aug 03, 2022
Merger
10→1
Aug 03, 2022
Merger
10→1
Date
Type
Ratio
Aug 03, 2022
Merger
10→1
Aug 03, 2022
Merger
10→1
Aug 03, 2022
Merger
10→1
FAQs
Who are the top five shareholders of Evogene Ltd?
The top five shareholders of Evogene Ltd are:
Recanati (Leon Yehuda) holds 83.89K shares, accounting for 0.96% of the total shares.
Citadel Advisors LLC holds 21.37K shares, accounting for 0.25% of the total shares.
Jane Street Capital, L.L.C. holds 15.02K shares, accounting for 0.17% of the total shares.
Morgan Stanley & Co. LLC holds 15.16K shares, accounting for 0.17% of the total shares.
Two Sigma Investments, LP holds 21.09K shares, accounting for 0.24% of the total shares.
Recanati (Leon Yehuda) holds 83.89K shares, accounting for 0.96% of the total shares.
Citadel Advisors LLC holds 21.37K shares, accounting for 0.25% of the total shares.
Jane Street Capital, L.L.C. holds 15.02K shares, accounting for 0.17% of the total shares.
Morgan Stanley & Co. LLC holds 15.16K shares, accounting for 0.17% of the total shares.
Two Sigma Investments, LP holds 21.09K shares, accounting for 0.24% of the total shares.
What are the top three shareholder types of Evogene Ltd?
The top three shareholder types of Evogene Ltd are:
Recanati (Leon Yehuda)
Citadel Advisors LLC
Jane Street Capital, L.L.C.
Recanati (Leon Yehuda)
Citadel Advisors LLC
Jane Street Capital, L.L.C.
How many institutions hold shares of Evogene Ltd (EVGN)?
As of 2025Q4, 51 institutions hold shares of Evogene Ltd, with a combined market value of approximately 144.62K, accounting for 9.61% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.32%.
What is the biggest source of revenue for Evogene Ltd?
In FY2024, the -- business generated the highest revenue for Evogene Ltd, amounting to -- and accounting for --% of total revenue.
